Mixed View of “Dangling” Accelerated Approvals

A changing treatment landscape prompted members of the FDA's Oncologic Drugs Advisory Committee to recommend withdrawing accelerated approvals for two PD-1 inhibitors. The same panel, however, voted to maintain four other accelerated approvals after confirmatory trials showed signs, albeit not statistically significant, of clinical benefit.